LU93093I2 - Nécitumumab et ses dérivés pharmaceutiquement acceptables (portrazza) - Google Patents

Nécitumumab et ses dérivés pharmaceutiquement acceptables (portrazza) Download PDF

Info

Publication number
LU93093I2
LU93093I2 LU93093C LU93093C LU93093I2 LU 93093 I2 LU93093 I2 LU 93093I2 LU 93093 C LU93093 C LU 93093C LU 93093 C LU93093 C LU 93093C LU 93093 I2 LU93093 I2 LU 93093I2
Authority
LU
Luxembourg
Prior art keywords
portrazza
necitumumab
pharmaceutically acceptable
acceptable derivatives
derivatives
Prior art date
Application number
LU93093C
Other languages
English (en)
Original Assignee
Imclone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Inc filed Critical Imclone Systems Inc
Publication of LU93093I2 publication Critical patent/LU93093I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LU93093C 2004-03-19 2016-05-31 Nécitumumab et ses dérivés pharmaceutiquement acceptables (portrazza) LU93093I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55455504P 2004-03-19 2004-03-19
US62426404P 2004-11-02 2004-11-02
PCT/US2005/009583 WO2005090407A1 (fr) 2004-03-19 2005-03-21 Anticorps du recepteur du facteur de croissance anti-epidermique humain

Publications (1)

Publication Number Publication Date
LU93093I2 true LU93093I2 (fr) 2016-08-01

Family

ID=34964896

Family Applications (1)

Application Number Title Priority Date Filing Date
LU93093C LU93093I2 (fr) 2004-03-19 2016-05-31 Nécitumumab et ses dérivés pharmaceutiquement acceptables (portrazza)

Country Status (18)

Country Link
US (1) US7598350B2 (fr)
EP (2) EP1735348B1 (fr)
JP (1) JP4734319B2 (fr)
CN (1) CN103007279B (fr)
AU (1) AU2005224267B2 (fr)
CA (1) CA2560305C (fr)
CY (2) CY1113037T1 (fr)
DK (1) DK1735348T3 (fr)
ES (1) ES2387809T3 (fr)
HU (1) HUS000495I2 (fr)
LT (1) LTC1735348I2 (fr)
LU (1) LU93093I2 (fr)
MX (1) MXPA06010715A (fr)
NL (1) NL300819I2 (fr)
PL (1) PL1735348T3 (fr)
PT (1) PT1735348E (fr)
RU (1) RU2402569C2 (fr)
WO (1) WO2005090407A1 (fr)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
PL365999A1 (en) * 1999-05-14 2005-01-24 Imclone Systems Incorporated Treatment of refractory human tumors with epidermal growth factor receptor antagonists
WO2002011677A2 (fr) * 2000-08-09 2002-02-14 Imclone Systems Incorporated Traitement de maladies hyperproliferatives au moyen d'antagonistes du recepteur de facteur de croissance epidermique
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
ES2466716T3 (es) * 2002-11-08 2014-06-11 Ablynx N.V. Anticuerpos de un solo dominio estabilizados
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
EP2267032A3 (fr) * 2002-11-08 2011-11-09 Ablynx N.V. Procédé d'administration de polypeptides thérapeutiques et polypeptides correspondants
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
WO2004041862A2 (fr) * 2002-11-08 2004-05-21 Ablynx N.V. Anticorps a domaine unique diriges contre le facteur de necrose tumorale alpha et leurs utilisations
US20100003253A1 (en) * 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
EP1622941A2 (fr) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Procede de production d'un anticorps contre le recepteur du facteur de croissance epidermique
JP5198289B2 (ja) 2006-02-03 2013-05-15 イムクローン・リミテッド・ライアビリティ・カンパニー 前立腺癌の治療用アジュバントとしてのｉｇｆ−ｉｒアンタゴニスト
CN101058609B (zh) * 2006-05-26 2011-04-13 神州细胞工程有限公司 人源抗体及其表达
KR20090021298A (ko) * 2006-06-14 2009-03-02 임클론 시스템즈 인코포레이티드 항-ｅｇｆｒ 항체의 동결건조 제제
EP2068929A4 (fr) * 2006-09-15 2010-04-28 Life Science Pharmaceuticals Methode de detection et de traitement de troubles cutanes
US7820159B2 (en) * 2006-10-31 2010-10-26 Instiute of Virology of the Slovak Academy of Sciences MN/CA IX and EGFR pathway inhibition
WO2009067242A2 (fr) * 2007-11-20 2009-05-28 Imclone Llc Co-cristaux de fragment fab de l'anticorps 11f8 et du domaine extracellulaire de egfr et leurs utilisations
US20110189206A1 (en) * 2008-01-03 2011-08-04 Barbas Iii Carlos F Antibody Targeting Through a Modular Recognition Domain
ES2500640T3 (es) * 2008-02-20 2014-09-30 Arizona Cancer Therapeutics, Llc Uso de péptidos de fusión terapéuticos para el tratamiento y la prevención del cáncer
CN102170907A (zh) 2008-08-05 2011-08-31 东丽株式会社 用于治疗和预防癌症的药物组合物
DK2733492T3 (en) 2008-08-05 2016-04-25 Toray Industries Method for detection of cancer
JP5851842B2 (ja) 2009-01-12 2016-02-03 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. 改変した抗体組成物、それを作製および使用する方法
KR101108642B1 (ko) 2009-09-29 2012-02-09 주식회사 녹십자 표피 성장 인자 수용체에 특이적으로 결합하는 항체
CN101704891B (zh) 2009-11-11 2011-11-09 中国人民解放军军事医学科学院生物工程研究所 一种针对表皮生长因子受体的抗体及其编码基因与应用
CN101875696B (zh) 2009-11-11 2012-02-08 中国人民解放军军事医学科学院生物工程研究所 一种抗体及其制备方法与应用
CN101875695B (zh) * 2009-11-11 2012-07-04 中国人民解放军军事医学科学院生物工程研究所 一种抗体及其编码基因与应用
KR20120102125A (ko) * 2009-12-18 2012-09-17 사노피 Ｇｐｖｉ에 대한 신규한 길항제 항체 및 그의 ｆａｂ 단편 및 그의 용도
MX340015B (es) 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
PT2532367T (pt) 2010-02-04 2018-11-09 Toray Industries Agente farmacêutico para o tratamento e/ou prevenção do cancro
US9115200B2 (en) 2010-02-04 2015-08-25 Toray Industries, Inc. Pharmaceutical composition for treating cancer using a monoclonal antibody having immunological reactivity with CAPRIN-1
CA2788716C (fr) 2010-02-04 2019-06-18 Toray Industries, Inc. Composition pharmaceutique pour le traitement et/ou la prevention du cancer
BR112012018948B1 (pt) 2010-02-04 2021-12-14 Toray Industries, Inc Composições farmacêuticas, anticorpos, combinação farmacêutica, usos de uma composição farmacêutica, uso de um anticorpo e uso de uma combinação farmacêutica
WO2012018260A1 (fr) * 2010-08-05 2012-02-09 Universiteit Utrecht Holding B.V. Thérapie immunitaire ciblant le récepteur du facteur de croissance épidermique
KR20130096731A (ko) 2010-09-08 2013-08-30 할로자임, 아이엔씨 조건부 활성 치료적 단백질을 평가，확인 또는 진화시키는 방법
KR101273918B1 (ko) 2010-09-17 2013-06-13 강원대학교산학협력단 인간 항-상피세포성 성장인자수용체 Ｆａｂ 항체 및 이를 포함하는 종양 치료용 약학 조성물
EP2627674A4 (fr) 2010-10-12 2014-04-30 Arizona Biomedical Res Commission Peptides basés sur l'egfr
WO2012058592A2 (fr) 2010-10-29 2012-05-03 Immunogen, Inc. Molécules non antagonistes se liant au récepteur egf et immunoconjugués de celles-ci
WO2012058588A2 (fr) * 2010-10-29 2012-05-03 Immunogen, Inc. Nouvelles molécules se liant au récepteur egf et immunoconjugués de celles-ci
EP2670426B1 (fr) 2011-01-31 2017-05-10 The General Hospital Corporation Molécules trail multimodales et leurs utilisations en thérapies cellulaires
JP6088488B2 (ja) 2011-04-21 2017-03-01 シアトル ジェネティックス， インコーポレイテッド 新規な結合剤−薬物複合体（ａｄｃ）およびそれらの使用
CN106432506A (zh) 2011-05-24 2017-02-22 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
PL2740796T3 (pl) 2011-08-04 2017-10-31 Toray Industries Kompozycja farmaceutyczna do leczenia nowotworu i/lub zapobiegania nowotworowi
CA2844033C (fr) 2011-08-04 2021-07-27 Toray Industries, Inc. Procede de detection du cancer du pancreas
KR101968498B1 (ko) 2011-08-04 2019-04-12 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
PT2740489T (pt) 2011-08-04 2017-01-10 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro pancreático
JP6065590B2 (ja) 2011-08-04 2017-01-25 東レ株式会社 癌の治療及び／又は予防用医薬組成物
PT2740798T (pt) 2011-08-04 2017-03-13 Toray Industries Composição de fármaco para o tratamento e/ou a prevenção de cancro
PL2740795T3 (pl) 2011-08-04 2017-04-28 Toray Industries, Inc. Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi
SG11201402343SA (en) 2011-11-21 2014-06-27 Immunogen Inc Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
DK2818483T3 (en) 2012-02-21 2017-10-23 Toray Industries Medical composition for the treatment and / or prevention of cancer
IN2014KN01716A (fr) 2012-02-21 2015-10-23 Toray Industries
US9273130B2 (en) 2012-02-21 2016-03-01 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
BR112014021099A2 (pt) 2012-02-21 2020-12-01 Toray Industries, Inc anticorpo, composição farmacêutica, dna e método de tratamento e/ou prevenção de câncer e uso de um anticorpo
US20140170159A9 (en) 2012-03-08 2014-06-19 Ge Wei Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
PT2832365T (pt) 2012-03-30 2018-01-24 Toray Industries Composição farmacêutica para o tratamento e/ou prevenção do cancro hepático
US9428581B2 (en) 2012-03-30 2016-08-30 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of gallbladder cancer
EP2850105A4 (fr) * 2012-05-17 2016-03-16 Sorrento Therapeutics Inc Protéines de liaison antigéniques se liant à egfr
JP6103832B2 (ja) 2012-06-25 2017-03-29 Hoya株式会社 Ｅｇｆｒ結合性ペプチド
RU2646466C2 (ru) 2012-07-19 2018-03-05 Торэй Индастриз, Инк. Метод детекции рака
WO2014014086A1 (fr) 2012-07-19 2014-01-23 東レ株式会社 Procédé de détection de cancer
US9862932B2 (en) 2012-07-24 2018-01-09 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
US9921222B2 (en) 2012-07-31 2018-03-20 Crown Bioscience, Inc. (Taicang) Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-EGFR drug
WO2014035474A1 (fr) * 2012-08-30 2014-03-06 The General Hospital Corporation Compositions et méthodes de traitement du cancer
CN102993305B (zh) * 2012-11-16 2015-05-13 上海赛伦生物技术有限公司 人源抗人表皮生长因子受体抗体及其编码基因与应用
WO2014166029A1 (fr) * 2013-04-07 2014-10-16 永卓博济(上海)生物医药技术有限公司 Anticorps anti-récepteur du facteur de croissance épidermique
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
JP6447130B2 (ja) 2013-08-09 2019-01-09 東レ株式会社 癌の治療及び／又は予防用医薬組成物
EA201600252A1 (ru) 2013-09-12 2017-05-31 Галозим, Инк. Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
BR112016014293B1 (pt) 2013-12-20 2023-11-21 Intervet International B.V Região de fragmento cristalizável canino, anticorpo caninizado, e,composição farmacêutica
RU2698697C2 (ru) 2013-12-23 2019-08-29 Байер Фарма Акциенгезельшафт Конъюгаты связующего (ADC) с ингибиторами KSP
JP6447887B2 (ja) 2014-03-03 2019-01-09 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 二重特異性抗体及びその使用
KR102523934B1 (ko) * 2014-07-24 2023-04-20 2세븐티 바이오, 인코포레이티드 Bcma 키메릭 항원 수용체
CN108251431B (zh) * 2015-03-05 2020-12-08 北京百特美博生物科技有限公司 双载体系统及其用途
WO2016161440A2 (fr) 2015-04-03 2016-10-06 Arizona Cancer Therapeutics, Llc Peptides inhibiteurs à base d'egfr pour l'inactivation combinatoire de l'erbb 1, de l'erbb 2 et de l'erbb3
TW201703769A (zh) 2015-05-08 2017-02-01 美國禮來大藥廠 用於癌症的組合療法
MX2017017172A (es) 2015-06-22 2018-02-23 Bayer Pharma AG Conjugados de ligador-principio activo (adcs) y conjugados de ligador-profarmaco (apdcs) con grupos enzimaticamente escindibles.
AU2016282724A1 (en) 2015-06-23 2018-01-18 Bayer Pharma Aktiengesellschaft Targeted conjugates of KSP inhibitors
TW201716439A (zh) 2015-07-20 2017-05-16 美國禮來大藥廠 Ｈｅｒ３抗體
WO2017060322A2 (fr) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Conjugué anticorps-médicament (adc) inhibiteur de ptefb
WO2017160568A1 (fr) 2016-03-16 2017-09-21 Eli Lilly And Company Polythérapie comprenant le nécitumumab, un inhibiteur de cdk4/6, et l'abémaciclib, un inhibiteur d'egfr, destinée à être utilisée dans le traitement du cancer
WO2017161206A1 (fr) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugués contenant des anticorps à activité conditionnelle ou des fragments de liaison à un antigène associés, et procédés d'utilisation
AU2017236431A1 (en) 2016-03-24 2018-09-27 Bayer Pharma Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
CA3027445A1 (fr) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Conjugues anticorps-medicament specifiques (adc) avec inhibiteurs de ksp et des anticorps anti-cd123
CN110036030A (zh) * 2016-09-26 2019-07-19 英克隆有限责任公司 癌症的组合疗法
KR102556826B1 (ko) 2016-12-21 2023-07-18 바이엘 파마 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc)
JP7174704B2 (ja) 2016-12-21 2022-11-17 バイエル・アクチエンゲゼルシヤフト 酵素開裂基を有する細胞毒性活性剤のプロドラッグ
EP3558387B1 (fr) 2016-12-21 2021-10-20 Bayer Pharma Aktiengesellschaft Conjugués anticorps-principe actif (adc) spécifiques renfermant des inhibiteurs de ksp
JP7072792B2 (ja) * 2017-12-11 2022-05-23 国立大学法人神戸大学 二重特異性抗体
KR20210116437A (ko) 2018-11-20 2021-09-27 코넬 유니버시티 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도
CN113260379B (zh) * 2018-12-21 2022-09-02 浙江时迈药业有限公司 蛋白酶可切割的双特异性抗体及其用途
WO2021076620A1 (fr) 2019-10-15 2021-04-22 Eli Lilly And Company Lignées cellulaires mammifères déficientes en lipase/estérase modifiées par recombinaison
CN113527482B (zh) * 2020-04-17 2023-07-21 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
WO2022031783A2 (fr) * 2020-08-05 2022-02-10 Ohio State Innovation Foundation Polypeptides adaptateurs et méthodes d'utilisation de ces derniers
EP4223779A1 (fr) 2020-09-30 2023-08-09 Institute Of Zoology, Chinese Academy Of Sciences Récepteur antigénique chimérique ciblant l'egfr
WO2022140670A2 (fr) * 2020-12-23 2022-06-30 Phenomic Ai Anticorps anti-activine et leurs procédés d'utilisation

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
NL7802170A (nl) * 1977-04-18 1978-10-20 Hitachi Metals Ltd Sierraad.
US4510924A (en) * 1980-07-10 1985-04-16 Yale-New Haven Hospital, Inc. Brachytherapy devices and methods employing americium-241
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5866363A (en) * 1985-08-28 1999-02-02 Pieczenik; George Method and means for sorting and identifying biological information
US4816401A (en) * 1985-09-09 1989-03-28 University Of Rochester Serum free cell culture medium
CA1275922C (fr) * 1985-11-28 1990-11-06 Harunobu Amagase Traitement du cancer
US4846782A (en) * 1986-03-14 1989-07-11 Schering Corporation Treatment of cancer with interferon and radiotherapy
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4763642A (en) * 1986-04-07 1988-08-16 Horowitz Bruce S Intracavitational brachytherapy
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5470571A (en) * 1988-01-27 1995-11-28 The Wistar Institute Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
WO1989009622A1 (fr) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Anticorps chimeriques specifiques au recepteur il-2
WO1989009825A1 (fr) 1988-04-16 1989-10-19 Celltech Limited Procede de production de proteines d'adn recombinant
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2133271T3 (es) * 1989-07-06 1999-09-16 Univ California Receptores para factores de crecimiento de fibroblastos.
US5705157A (en) * 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5196446A (en) * 1990-04-16 1993-03-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Certain indole compounds which inhibit EGF receptor tyrosine kinase
JPH05506857A (ja) 1990-04-16 1993-10-07 ローヌ―プーラン　ローラー　インターナショナル　（ホウルディングス）インコーポレイテッド Ｅｇｆレセプタチロシンキナーゼを阻害するスチリル―置換単環式および二環式複素アリール化合物
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
HU219537B (hu) * 1991-03-06 2001-05-28 Merck Patent Gmbh. Humanizált és kiméra monoklonális antitestek, azokat tartalmazó gyógyászati készítmények, az antitesteket kódoló szekvenciát tartalmazó expressziós vektorok, valamint eljárás az antitestek előállítására
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
DK0590058T3 (da) * 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5559235A (en) * 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
WO1993011236A1 (fr) 1991-12-02 1993-06-10 Medical Research Council Production d'anticorps anti-auto-antigenes a partir de repertoires de segments d'anticorps affiches sur phage
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
DK0672142T3 (da) * 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5855885A (en) * 1993-01-22 1999-01-05 Smith; Rodger Isolation and production of catalytic antibodies using phage technology
US5550114A (en) * 1993-04-02 1996-08-27 Thomas Jefferson University Epidermal growth factor inhibitor
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
EP0746554A1 (fr) * 1994-02-23 1996-12-11 Pfizer Inc. Derives de la quinazoline a substitution 4-heterocyclyle, procedes d'elaboration et utilisations correspondantes comme agents anticancereux
AU2096895A (en) * 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
RU2170257C2 (ru) * 1994-03-17 2001-07-10 Мерк Патент Гмбх Анти-эфрр одноцепочечный fv, химерное анти-эфрр антитело и способ его получения, фармацевтическая композиция для лечения опухолей, средство для диагностики локализации или оценки роста опухоли
JP3249007B2 (ja) * 1994-03-17 2002-01-21 富士通株式会社 半導体装置、その特性評価方法及び設計方法
US5656655A (en) * 1994-03-17 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Styryl-substituted heteroaryl compounds which inhibit EGF receptor tyrosine kinase
US5869465A (en) * 1994-04-08 1999-02-09 Receptagen Corporation Methods of receptor modulation and uses therefor
US5468754A (en) * 1994-04-19 1995-11-21 Bionumerik Pharmaceuticals, Inc. 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
US5604233A (en) * 1994-04-28 1997-02-18 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5663144A (en) * 1995-05-03 1997-09-02 The Trustees Of The University Of Pennsylvania Compounds that bind to p185 and methods of using the same
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
EP0888349B1 (fr) * 1996-01-23 2002-05-22 Novartis AG Pyrrolopyrimidines et leurs procedes de preparation
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9707800D0 (en) * 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
US5925566A (en) * 1996-06-06 1999-07-20 University Of Massachusetts Non-activated receptor complex proteins and uses thereof
WO1997049688A1 (fr) 1996-06-24 1997-12-31 Pfizer Inc. Derives tricycliques substitues par phenylamino, destines au traitement des maladies hyperproliferatives
US6004967A (en) * 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
DE69839338T2 (de) 1997-02-05 2008-07-10 Warner-Lambert Company Llc Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation
US5942602A (en) * 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
US20030105057A1 (en) * 1997-03-19 2003-06-05 Yale University Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment
US5914269A (en) * 1997-04-04 1999-06-22 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of epidermal growth factor receptor expression
US20020173629A1 (en) * 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6417168B1 (en) * 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
WO1999060023A1 (fr) * 1998-05-15 1999-11-25 Imclone Systems Incorporated Traitement de tumeurs humaines a l'aide d'un rayonnement et d'inhibiteurs de tyrosine kinases de recepteurs du facteur de croissance
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
DK1117659T3 (da) 1998-09-29 2004-03-22 Wyeth Corp Substituerede 3-cyanoquinoliner som hæmmere af proteintyrosinkinaser
NZ512189A (en) 1998-11-19 2003-10-31 Warner Lambert Co N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4- yl-propoxy)-quinazolin-6-yl]-acrylamide useful as an irreversible inhibitor of tyrosine kinases
US7396810B1 (en) * 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
PL365999A1 (en) * 1999-05-14 2005-01-24 Imclone Systems Incorporated Treatment of refractory human tumors with epidermal growth factor receptor antagonists
DK1054018T3 (da) 1999-05-18 2009-05-18 Dyax Corp Fab-fragmentbiblioteker og fremgangsmåde til anvendelse deraf
US6627196B1 (en) * 1999-08-27 2003-09-30 Genentech, Inc. Dosages for treatment with anti-ErbB2 antibodies
WO2002011677A2 (fr) 2000-08-09 2002-02-14 Imclone Systems Incorporated Traitement de maladies hyperproliferatives au moyen d'antagonistes du recepteur de facteur de croissance epidermique
JP2004529610A (ja) * 2000-10-13 2004-09-30 ユーエイビー リサーチ ファンデーション ヒト抗上皮増殖因子受容体一本鎖抗体
AU2002239486A1 (en) * 2000-12-08 2002-06-18 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
WO2002087618A1 (fr) * 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Methode de prevention et de traitement du cancer
CZ200438A3 (cs) * 2001-06-13 2004-06-16 Genmab A/S Název neuveden
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
DE10163459A1 (de) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
BR0307216A (pt) * 2002-01-28 2005-12-20 Medarex Inc Anticorpos monoclonais humanos para antìgeno de membrana especìfica de próstata (psma)
PT1916001E (pt) 2002-03-04 2011-07-18 Imclone Llc Anticorpos humanos específicos para kdr e suas utilizações
ATE494000T1 (de) * 2002-03-08 2011-01-15 Max Planck Gesellschaft Verwendung von egfr transaktivierungsinhibitoren für menschlichen krebs
US20060264353A1 (en) * 2002-03-21 2006-11-23 Maxey Kirk M Prostaglandin f2alpha analogs and their use in combination with antimicrobial proteins for the treatment of glaucoma and intraocular hypertension
AU2003241898A1 (en) * 2002-06-03 2003-12-19 Mitsubishi Pharma Corporation PREVENTIVES AND/OR REMEDIES FOR SUBJECTS WITH THE EXPRESSION OR ACTIVATION OF Her2 AND/OR EGFR
JP4660189B2 (ja) * 2002-07-03 2011-03-30 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 抗血小板自己抗体およびそのインヒビターに関連する組成物、方法およびキット
MXPA05003796A (es) * 2002-10-10 2006-02-22 Merck Patent Gmbh Anticuerpos anti-erb-b biespecificos y su uso en terapia de tumor.
ES2527871T3 (es) 2003-05-01 2015-02-02 Imclone Llc Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana
EP1493445A1 (fr) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition de l'activation de l'EGFR, cette activation étant dépendante d'un ligand et étant induite par le stress
ES2352697T3 (es) * 2003-11-07 2011-02-22 Ablynx N.V. Anticuerpos de dominio único de camelidae vhh dirigidos contra el receptor del factor de crecimiento epidérmico y usos de los mismos.
DE10355904A1 (de) * 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
CN1953768B (zh) * 2004-02-12 2010-10-13 默克专利有限公司 抗-egfr抗体的高浓缩液体制剂
TW200533339A (en) * 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
JP5835204B2 (ja) 2012-12-20 2015-12-24 信越化学工業株式会社 レジスト材料及びこれを用いたパターン形成方法

Also Published As

Publication number Publication date
US20070264253A1 (en) 2007-11-15
PT1735348E (pt) 2012-07-24
CY2016016I1 (el) 2016-12-14
JP4734319B2 (ja) 2011-07-27
CN103007279B (zh) 2017-01-11
EP1735348A1 (fr) 2006-12-27
JP2008500815A (ja) 2008-01-17
CY1113037T1 (el) 2016-04-13
HUS1600030I1 (hu) 2016-07-28
AU2005224267A1 (en) 2005-09-29
EP2332990A1 (fr) 2011-06-15
EP1735348B1 (fr) 2012-06-20
NL300819I2 (fr) 2016-07-21
WO2005090407A1 (fr) 2005-09-29
HUS000495I2 (hu) 2021-03-29
CA2560305A1 (fr) 2005-09-29
AU2005224267B2 (en) 2011-07-21
DK1735348T3 (da) 2012-07-16
MXPA06010715A (es) 2007-05-23
CN103007279A (zh) 2013-04-03
PL1735348T3 (pl) 2012-11-30
US7598350B2 (en) 2009-10-06
RU2006137060A (ru) 2008-04-27
ES2387809T3 (es) 2012-10-02
RU2402569C2 (ru) 2010-10-27
CA2560305C (fr) 2016-07-05
LTC1735348I2 (lt) 2017-11-10
WO2005090407A8 (fr) 2005-12-01
CY2016016I2 (el) 2016-12-14

Similar Documents

Publication Publication Date Title
LU93093I2 (fr) Nécitumumab et ses dérivés pharmaceutiquement acceptables (portrazza)
LU93189I2 (fr) Ixekizumab et ses dérivés pharmaceutiquement acceptables (TALTZ)
LU92871I2 (fr) Fumarate de diméthyle et ses dérivés pharmaceutiquement acceptables (tecfidera)
LU92517I2 (fr) Delamanide et ses dérivés pharmaceutiquement acceptables
LU92513I2 (fr) Sofosbuvir et ses dérivés pharmaceutiquement acceptables (solvaldi)
LUC00127I2 (fr) Dacomitinib et ses derives pharmaceutiquement accepatbles ( vizimpro )
LU92336I2 (fr) Trastuzumab emtansine et ses dérivés pharmaceutiquement acceptables (KADCYLA)
LU92326I2 (fr) Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS)
LU92419I2 (fr) Riociguat et ses dérivés pharmaceutiquement acceptables (ADEMPAS®)
LU93096I2 (fr) Evolocumab et ses dérivés pharmaceutiquement acceptables (repatha)
LU92381I2 (fr) Macitentan et ses dérivés pharmaceutiquement acceptables (OPSUMIT)
LU91883I2 (fr) Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®)
IS2599B (is) 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess
LU92024I2 (fr) Pasireotide et ses dérivés pharmaceutiquement acceptables (SIGNIFOR)
LU91624I2 (fr) Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS®)
LU91757I2 (fr) Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)
LU92634I2 (fr) Flutémétamol (18f) et ses dérivés pharmaceutiquement acceptables (vizamyl)
ATE478870T1 (de) Spiroindolinpiperidinderivate
ATE460418T1 (de) Heterocyclocarboxamidderivate
DK1551802T3 (da) Indol-3-svovlderivater
ATE467631T1 (de) Chinuclidinamidderivate
ATE438644T1 (de) Chinazolinderivate
DK1474408T3 (da) N-Phenyl-2-pyrimidinaminderivater
MX2007007613A (es) Formulaciones farmaceuticas.
NO20054095D0 (no) Pyridyloksymetyl og benzioksazolazabicyklisk derivater